Antibodies to the Plasmodium falciparum Proteins MSPDBL1 and MSPDBL2 Opsonize Merozoites, Inhibit Parasite Growth, and Predict Protection from Clinical Malaria

Journal of Infectious Diseases

Volumn 212, Issue 3, 2015, Pages 406-415

  Chiu, Chris Y H ^a,b   Hodder, Anthony N ^a,b   Lin, Clara S ^a,b   Hill, Danika L ^a,b   Li Wai Suen, Connie S N ^a   Schofield, Louis ^a,c   Siba, Peter M ^d   Mueller, Ivo ^a,e   Cowman, Alan F ^a,b   Hansen, Diana S ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c JAMES COOK UNIVERSITY   (Australia)

^d PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

antibodies; immunity; malaria; MSPDBL1; MSPDBL2; Plasmodium falciparum

Indexed keywords

ARTESUNATE; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; MEROZOITE SURFACE PROTEIN DUFFY BINDING LIKE 1 PROTEIN; MEROZOITE SURFACE PROTEIN DUFFY BINDING LIKE 2 PROTEIN; MICROORGANISM PROTEIN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CHILD; CONTROLLED STUDY; EFFECTOR CELL; ERYTHROCYTE; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALARIA; MEROZOITE; NONHUMAN; PAPUA NEW GUINEA; PARASITE DEVELOPMENT; PARASITE GROWTH; PHAGOCYTOSIS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN DOMAIN; REINFECTION; RISK REDUCTION; BLOOD; COHORT ANALYSIS; IMMUNOLOGY; KAPLAN MEIER METHOD; MALARIA, FALCIPARUM; PARASITOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ANTIBODIES, PROTOZOAN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; PAPUA NEW GUINEA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS;

EID: 84939477452     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv057     Document Type: Article

References (30)

1. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature 2002; 415:673-9.
2. White NJ, Ho M. The pathophysiology of malaria. Adv Parasitol 1992; 31:83-173.
3. Baird JK. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. Parasitol Today 1995; 11:105-11.
4. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol 2006; 28:51-60.
5. Cohen S, Mc GI, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192:733-7.
6. Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. Cell 2006; 124:755-66.
7. Singh S, Soe S,Weisman S, et al. A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum. PLoS One 2009; 4:e5410.
8. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, et al. Merozoite surface protein-3: A malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994; 84:1594-602.
9. Hodder AN, Czabotar PE, Uboldi AD, et al. Insights into Duffy binding-like domains through the crystal structure and function of the merozoite surface protein MSPDBL2 from Plasmodium falciparum. J Biol Chem 2012; 287:32922-39.
10. Batchelor JD, Zahm JA, Tolia NH. Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC. Nat Struct Mol Biol 2011; 18:908-14.
11. Maier AG, Baum J, Smith B, et al. Polymorphisms in erythrocyte binding antigens 140 and 181 affect function and binding but not receptor specificity in Plasmodium falciparum. Infect Immu 2009; 77:1689-99.
12. Tolia NH, Enemark EJ, Sim BK, Joshua-Tor L. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. Cell 2005; 122:183-93.
13. Wickramarachchi T, Cabrera AL, Sinha D, et al. A novel Plasmodium falciparum erythrocyte binding protein associated with the merozoite surface, PfDBLMSP. Int J Parasitol 2009; 39:763-73.
14. Lin CS, Uboldi AD, Marapana D, et al. The merozoite surface protein 1 complex is a platform for binding to human erythrocytes by Plasmodium falciparum. J Biol Chem 2014; 289:25655-69.
15. Sakamoto H, Takeo S, Maier AG, et al. Antibodies against a Plasmodium falciparum antigen PfMSPDBL1 inhibit merozoite invasion into human erythrocytes. Vaccine 2012; 30:1972-80.
16. Amambua-Ngwa A, Tetteh KK, Manske M, et al. Population genomic scan for candidate signatures of balancing selection to guide antigen characterization in malaria parasites. PLoS Genet 2012; 8:e1002992.
17. Ochola LI, Tetteh KK, Stewart LB, et al. Allele frequency-based and polymorphism-versus-divergence indices of balancing selection in a new filtered set of polymorphic genes in Plasmodium falciparum. Mol Biol Evol 2010; 27:2344-51.
18. Tetteh KK, Stewart LB, Ochola LI, et al. Prospective identification of malaria parasite genes under balancing selection. PLoS One 2009; 4: e5568.
19. Tetteh KK, Osier FH, Salanti A, et al. Analysis of antibodies to newly described Plasmodium falciparum merozoite antigens supports MSPDBL2 as a predicted target of naturally acquired immunity. Infect Immun 2013; 81:3835-42.
20. Michon P, Cole-Tobian JL, Dabod E, et al. The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg 2007; 76:997-1008.
21. Hill DL, Eriksson EM, Carmagnac AB, et al. Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites. PLoS One 2012; 7:e51692.
22. Hill DL, Eriksson EM, Schofield L. High yield purification of Plasmodium falciparum merozoites for use in opsonizing antibody assays. J Vis Exp 2014; 89:e51590.
23. Richards JS, Arumugam TU, Reiling L, et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol 2013; 191:795-809.
24. Roussilhon C, Oeuvray C, Muller-Graf C, et al. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med 2007; 4:e320.
25. Stanisic DI, Richards JS, McCallum FJ, et al. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 2009; 77:1165-74.
26. Hill DL, Eriksson EM, LiWai Suen CS, et al. Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria. PLoS One 2013; 8:e74627.
27. Demanga CG, Daher LJ, Prieur E, et al. Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans. Infect Immun 2010; 78:486-94.
28. Singh S, Soe S, Mejia JP, et al. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J Infect Dis 2004; 190:1010-8.
29. Burgess BR, Schuck P, Garboczi DN. Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. J Biol Chem 2005; 280:37236-45.
30. Kauth CW,Woehlbier U, Kern M, et al. Interactions between merozoite surface proteins 1, 6, and 7 of the malaria parasite Plasmodium falciparum. J Biol Chem 2006; 281:31517-27.